• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Sanofi, Novo, Lilly Shape up for Big Insulin Fight

Article

Competition is ramping up in the multibillion-dollar market for long-lasting insulins, with Novo Nordisk and Eli Lilly lining up new products that could trump Sanofi's top-seller Lantus.

Worldwide, Lantus has some 80 percent of the market for long-acting, or basal, insulins used to treat diabetes and the product had sales of around $5 billion last year. Now rivals are closing in.

Read the full story:

http://hcp.lv/KahW6a

Source: Reuters

Related Videos
Ciara Zachary, PhD, MPH
Hearn Jay Cho, MD, PhD
Nicoletta Colombo, MD, PhD
Eleanor Perfetto, PhD
William Schpero, PhD, MPhil, MPH
Screenshot of an interview with Stephen Nicholls, MBBS, PhD
Screenshot of an interview with Martha Gulati, MD
Screenshot of an interview with Vallerie McLaughlin, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.